Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond.

IF 2.5 3区 医学 Q3 PHARMACOLOGY & PHARMACY
Expert Opinion on Pharmacotherapy Pub Date : 2024-06-01 Epub Date: 2024-06-27 DOI:10.1080/14656566.2024.2373354
Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna
{"title":"Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond.","authors":"Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna","doi":"10.1080/14656566.2024.2373354","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The use of the current available therapies for psoriasis management may sometimes be limited by reduced patients' compliance, safety issues for patients' comorbidities, primary lack of efficacy, loss of effectiveness, development of side effects. In this context, several clinical trials investigating the use of both topical and systemic therapies are ongoing, and other new drugs will be approved soon.</p><p><strong>Areas covered: </strong>The aim of this manuscript is to review current literature and to provide an overview of the current and future trends in psoriasis treatment. A comprehensive review of the English-language medical literature was performed using Pubmed and clinicaltrials.gov databases.</p><p><strong>Expert opinion: </strong>Although several therapies are currently available for psoriasis' treatment, unmet needs still exist for patients with moderate and severe psoriasis and hence expanding the therapeutic armamentarium is desirable for a more personalized approach. The ongoing development of innovative therapies could provide effective and safe therapies in the future enhancing the therapeutic management of moderate-severe unresponsive psoriasis.</p>","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14656566.2024.2373354","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The use of the current available therapies for psoriasis management may sometimes be limited by reduced patients' compliance, safety issues for patients' comorbidities, primary lack of efficacy, loss of effectiveness, development of side effects. In this context, several clinical trials investigating the use of both topical and systemic therapies are ongoing, and other new drugs will be approved soon.

Areas covered: The aim of this manuscript is to review current literature and to provide an overview of the current and future trends in psoriasis treatment. A comprehensive review of the English-language medical literature was performed using Pubmed and clinicaltrials.gov databases.

Expert opinion: Although several therapies are currently available for psoriasis' treatment, unmet needs still exist for patients with moderate and severe psoriasis and hence expanding the therapeutic armamentarium is desirable for a more personalized approach. The ongoing development of innovative therapies could provide effective and safe therapies in the future enhancing the therapeutic management of moderate-severe unresponsive psoriasis.

银屑病治疗的新型药物疗法和突破:2024 年及以后。
导言:由于患者的依从性降低、患者合并症的安全性问题、主要疗效缺乏、疗效丧失、副作用产生等原因,目前可用的银屑病治疗方法的使用有时会受到限制。在这种情况下,一些研究局部和全身疗法的临床试验正在进行中,其他新药也将很快获得批准:本手稿旨在回顾当前文献,概述银屑病治疗的当前和未来趋势。我们使用 Pubmed 和 clinicaltrials.gov 数据库对英文医学文献进行了全面综述:专家观点:尽管目前有多种疗法可用于银屑病治疗,但中度和重度银屑病患者的需求仍未得到满足,因此,扩大治疗手段范围以采用更个性化的方法是可取的。创新疗法的不断开发可在未来提供有效、安全的疗法,从而加强对中度和重度无反应银屑病的治疗管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
3.10%
发文量
163
审稿时长
4-8 weeks
期刊介绍: Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信